CervoMed reports Q3 2024 net loss $4.8M; cash $46.7M; RewinD-LB data due Dec 2024

CervoMed Inc.

2024-Q3 EPS reported -$1.22 revenue$7,575,972

Net loss $4.8M in Q3 2024 vs net income $2.2M in Q3 2023; R&D expenses rose to $5.1M from $1.8M.
Cash, cash equivalents and marketable securities $46.7M at Sep 30, 2024 (vs $50.9M at Jun 30); cash runway through 2025.
RewinD-LB Phase 2b top-line data expected Dec 2024; last patient visit Oct 2024. Plan Phase 3 mid-2025 and Phase 2a for stroke Q1 2025.
Awarded Prix Galien USA 2024 Best Startup on Nov 8, 2024, recognizing innovation in DLB treatment development.
Appointed Claudia Ordonez (SVP Medical) and Mark De Rosch (SVP Regulatory); granted options for 56,959 shares at $12.53.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.